A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

被引：0
作者：
Claire F. Verschraegen
Andrzej P. Kudelka
Wei Hu
Monique Vincent
John J. Kavanagh
Evelyne Loyer
Luc Bastien
A. Duggal
R. De Jager
机构：
[1] The University of Texas M. D. Anderson Cancer Center,Section of Gynecologic Medical Oncology
[2] The University of Texas M. D. Anderson Cancer Center,Department of Radiology
[3] MDS Pharma Services,undefined
[4] Daiichi Pharmaceutical Corporation,undefined
[5] University of New Mexico Cancer Research and Treatment Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2004年 / 53卷
关键词：
Camptothecin; Ovarian neoplasm; Topotecan resistance; Pharmacokinetics; Exatecan mesylate; DX-8951f;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 7
页数：6
相关论文
共 27 条
  • [21] Ishii undefined(2000)undefined Anticancer Drugs 11 353-undefined
  • [22] Maliepaard undefined(2001)undefined Clin Cancer Res 7 935-undefined
  • [23] Kumazawa undefined(1995)undefined Proc Am Assoc Cancer Res 36 A2627-undefined
  • [24] Mitsui undefined(1993)undefined Proc Am Assoc Cancer Res 34 A2510-undefined
  • [25] van undefined(2002)undefined Biochem Pharmacol 64 1267-undefined
  • [26] Takiguchi undefined(1997)undefined Jpn J Cancer Res 88 760-undefined
  • [27] Kumazawa undefined(1998)undefined Cancer Chemother Pharmacol 42 210-undefined
123